✦ LIBER ✦

Trial of platelet-inhibiting drug in scleroderma double-blind study with dipyridamole and aspirin

✍ Scribed by Victoria L. Beckett; Doyt L. Conn; Valentin Fuster; Philip J. Osmundson; Cameron G. Strong; Edmund Y. S. Chao; James H. Chesebro; W. Michael O'Fallon

Publisher: John Wiley and Sons
Year: 1984
Tongue: English
Weight: 629 KB
Volume: 27
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.1780271009

No coin nor oath required. For personal study only.

✦ Synopsis

In a randomized, double-blind, controlled study, 28 patients with early scleroderma received dipyridamole (225 mg/day) and aspirin (975 mg/day) or placebo for 1-2 years. No significant clinical or objective laboratory improvement was noted in either group. Platelet survival time, plasma renin activity, and coagulation tests were not predictive of disease course. Biomechanical and vascular tests of the hands correlated with clinical extent of skin induration and presence of finger ulcers, respectively.

The cause of systemic sclerosis (scleroderma) is unknown, and to date there is no effective therapy for it. A vascular hypothesis for its pathogenesis has been

~_ _ _

From the Mayo Clinic and Mayo Foundation,

📜 SIMILAR VOLUMES

Interferon-α does not improve outcome at

Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial

✍ Carol M. Black; Alan J. Silman; Ariane I. Herrick; Christopher P. Denton; Helen 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 1 views

## Objective: To determine whether interferon-alpha (ifnalpha) reduces the severity of skin involvement in early (<3 years) diffuse scleroderma. ## Methods: In a randomized, placebo-controlled, double-blind trial, 35 patients with early scleroderma received subcutaneous injections of either ifnal

A 24-week, double-blind, placebo-control

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease—pilot study

✍ Vee. P. Prasher; Adam Huxley; M. S. Haque 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

## Abstract ## Background Donepezil Hydrochloride (Aricept) is a selective anticholinesterase inhibitor developed for the treatment of Alzheimer's disease (AD). This study investigated the safety and efficacy of the drug to treat Down syndrome (DS) adults with mild to moderate AD. ## Method This

GCP audit findings - case study no. 2. A

GCP audit findings - case study no. 2. A multicentre double-blind study to compare the safety and efficacy of drug X with marketed drug Y in patients with unstable angina undergoing cardiovascular surgery

✍ Wendy Bohaychuk; Graham Ball 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 2 views

Efficacy and safety of entecavir compare

Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

✍ Guangbi Yao; Chengwei Chen; Weilun Lu; Hong Ren; Deming Tan; Yuming Wang; Daozhe 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 223 KB

Efficacy and safety of entecavir compare

Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

✍ Guangbi Yao; Chengwei Chen; Weilun Lu; Hong Ren; Deming Tan; Yuming Wang; Daozhe 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 89 KB

A multicenter, randomized, double-blind

A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a phase III clinical trial

✍ Daniel L. Rubin; Terry S. Desser; Richard Semelka; Jeffrey Brown; Hanh V. Nghiem 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 3 views